Market openADR
Belite Bio Inc. ADS/$BLTE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Belite Bio Inc. ADS
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Ticker
$BLTE
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
25
Website
BLTE Metrics
BasicAdvanced
$1.9B
-
-$1.18
-1.54
-
Price and volume
Market cap
$1.9B
Beta
-1.54
52-week high
$70.99
52-week low
$49.00
Average daily volume
41K
Financial strength
Current ratio
24.31
Quick ratio
24.087
Long term debt to equity
0.179
Total debt to equity
0.368
Interest coverage (TTM)
-1,999.80%
Management effectiveness
Return on assets (TTM)
-20.26%
Return on equity (TTM)
-30.60%
Valuation
Price to book
12.74
Price to tangible book (TTM)
12.74
Price to free cash flow (TTM)
-60.672
Growth
Earnings per share change (TTM)
-0.50%
3-year earnings per share growth (CAGR)
5.43%
BLTE News
AllArticlesVideos
Belite Bio, Inc. (BLTE) Q4 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewsWire·1 month ago
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Belite Bio Inc. ADS stock?
Belite Bio Inc. ADS (BLTE) has a market cap of $1.9B as of April 23, 2025.
What is the P/E ratio for Belite Bio Inc. ADS stock?
The price to earnings (P/E) ratio for Belite Bio Inc. ADS (BLTE) stock is 0 as of April 23, 2025.
Does Belite Bio Inc. ADS stock pay dividends?
No, Belite Bio Inc. ADS (BLTE) stock does not pay dividends to its shareholders as of April 23, 2025.
When is the next Belite Bio Inc. ADS dividend payment date?
Belite Bio Inc. ADS (BLTE) stock does not pay dividends to its shareholders.
What is the beta indicator for Belite Bio Inc. ADS?
Belite Bio Inc. ADS (BLTE) has a beta rating of -1.54. This means that it has an inverse relation to market volatility.